Abstracts Archive - Page 356 of 2425 - ACR Meeting Abstracts

Abstract Number: 2486 • ACR Convergence 2023
Should SLE Patients Entering Clinical Trials Be Required to Have at Least One BILAG a And/or Two BILAG B Scores?
Ewa Olech¹ and Joan Merrill², ¹IQVIA, Rheumatology Consultants, PLLC, Las Vegas, NV, ²Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: High placebo response rates have challenged interpretation of clinical trial results in SLE and may have contributed to failure of some effective treatments. One…
Abstract Number: 2489 • ACR Convergence 2023
Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Achievement and Sustained Response with Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in a Phase 2 Trial in SLE
Cristina Arriens¹, Ronald van Vollenhoven², Alice B. Gottlieb³, Coburn Hobar⁴, Samantha Pomponi⁴, Ravi Koti⁵, Thomas Wegman⁶ and Victoria P. Werth⁷, ¹Oklahoma Medical Research Foundation and University of Oklahoma Health Sciences Center, Department of Arthritis & Clinical Immunology, Oklahoma City, OK, ²Amsterdam University Medical Centers, Amsterdam, Netherlands, ³Icahn School of Medicine at Mount Sinai, New York, NY, ⁴Bristol Myers Squibb, Princeton, NJ, ⁵Syneos Health, Morrisville, NC, ⁶Bristol Myers Squibb, Beaver Falls, PA, ⁷University of Pennsylvania, Wynnewood, PA
Background/Purpose: Deucravacitinib is a first-in-class, oral, selective, allosteric tyrosine kinase 2 inhibitor approved in multiple countries for the treatment of adults with plaque psoriasis. A…
Abstract Number: 2490 • ACR Convergence 2023
Safety and Efficacy of Mycophenolate Mofetil in New-onset Systemic Lupus Erythematosus with High Titer of Anti-dsDNA Antibody and Without Major Organ Involvement: A Multicenter Randomized Controlled Trial
Junna Ye¹, Yijun You², Zhuochao Zhou², Jingyi Wu², Fan wang² and Chengde Yang², ¹Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China, ²Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Background/Purpose: Previous clinical trials of mycophenolate mofetil (MMF) in SLE were mainly focused on lupus nephritis (LN) (patients have been diagnosed with LN). In the…
Abstract Number: 2396 • ACR Convergence 2023
Diagnostic Performance of a Newly-Launched Canadian Fast-Track Ultrasound Clinic Performed by Rheumatologists for Diagnosis of Giant Cell Arteritis
Jean-Charles Mourot¹, Sai Yan Yuen², Mihaela Popescu³ and Nicolas Richard⁴, ¹Université de Montréal, Mont-Royal, QC, Canada, ²Maisonneuve-Rosemont Hospital, Mont-Royal, QC, Canada, ³Maisonneuve Rosemont Hospital, Longueuil, QC, Canada, ⁴Hopital Maisonneuve Rosemont, Montreal, QC, Canada
Background/Purpose: Giant Cell Arteritis (GCA) poses diagnostic challenges for clinicians as there is no universal gold standard. We hypothesize that launching a Fast-Track Ultrasound (US)…
Abstract Number: 2495 • ACR Convergence 2023
Unbiased Proteomic Approach to Identify Novel Biomarkers of Disease Activity in ANCA- Associated Vasculitis
Natalie Atallah¹, Vahe Panossian², Xiaoqing Fu¹, Claire Cook¹ and Zachary Wallace³, ¹Massachusetts General Hospital, Boston, MA, ²American University of Beirut, Beirut, Lebanon, ³Massachusetts General Hospital, Newton, MA
Background/Purpose: Identifying novel biomarkers of disease activity could improve outcomes by facilitating personalized approaches to treatment decisions in ANCA-associated vasculitis. Biomarkers of disease activity used…
Abstract Number: 2494 • ACR Convergence 2023
Complement mRNA Expression in Patients with ANCA-associated Glomerulonephritis
Salem Almaani¹, Arnon Arazi², Huijuan Song³, Pearlly Yan³, Estela Puchulu-Campanella³, Hubao Wang³, Lynn Fussner³, Samir Parikh³ and Brad Rovin³, ¹Ohio State University Medical Center, Columbus, OH, ²Broad Institute of MIT and Harvard, Melrose, MA, ³Ohio State University, Columbus, OH
Background/Purpose: The role of complement in patients with ANCA-associated vasculitis (AAV) has been increasingly appreciated and led to the use of complement system antagonists as…
Abstract Number: 2268 • ACR Convergence 2023
Mental Illness and Outcomes of COVID-19 in Patients with Systemic Lupus Erythematosus: A Global Multicenter Cohort Study
Hsin-Hua Chen, Taichung Veterans General Hospital, Taichung, Taiwan
Background/Purpose: Poor COVID-19 outcomes in patients with systemic lupus erythematosus (SLE) has been found to be associated with glucocorticoid dose, male sex, older age, mycophenolate,…
Abstract Number: 2488 • ACR Convergence 2023
Efficacy and Safety of ABBV-599 High Dose (Elsubrutinib 60 mg and Upadacitinib 30 mg) and Upadacitinib Monotherapy for the Treatment of Systemic Lupus Erythematosus: A Phase 2, Double-blind, Placebo-controlled Trial
Joan Merrill¹, Yoshiya Tanaka², David D'Cruz³, Karina Vila-Rivera⁴, Daniel Siri⁵, Xiaofeng Zeng⁶, Kristin D'Silva⁷, Ling Cheng⁷, Thierry Sornasse⁷, Thao Doan⁷, Denise Kruzikas⁷ and Alan Friedman⁷, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²University of Occupational and Environmental Health, Kitakyushu, Japan, ³King's College London, London, United Kingdom, ⁴GCM Medical, San Juan, PR, ⁵CAICI SRL, Rosario, Argentina, ⁶Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ⁷AbbVie, Inc., North Chicago, IL
Background/Purpose: ABBV-599 is a novel combination of elsubrutinib (ELS; a selective BTK inhibitor) and upadacitinib (UPA; a JAK inhibitor) that targets non-overlapping signaling pathways associated…
Abstract Number: 2467 • ACR Convergence 2023
Quadriceps Muscle Fat Composition but Not Muscle Energetics Is Associated with Knee Osteoarthritis: Initial Results from the Study of Muscle, Mobility, and Aging
Giovanna Distefano¹, Daniel Evans², Peggy Cawthon², John Lynch², Thomas Link², Philip Kramer³, Stephanie Harrison², Bret Goodpaster⁴, Jane Cauley⁵, Theresa Mau², Paul Coen⁴, Lauren Sparks⁴ and Nancy Lane⁶, ¹AventisHealth, Orlando, FL, ²University of California San Francisco, San Francisco, CA, ³Wake Forest, Winston-Salem, NC, ⁴Aventis Health, Orlando, FL, ⁵University of Pittsburgh, Pittsburgh, PA, ⁶University of California, Hillsborough, CA
Background/Purpose: Osteoarthritis (OA) remains the most common cause of joint pain and disability with age, and to date, effective treatments to reduce pain and slow…
Abstract Number: 2480 • ACR Convergence 2023
Definition of Rheumatoid Arthritis Flare Based on SDAI and CDAI
Victoria Konzett¹, Andreas Kerschbaumer², Josef S Smolen³, Eirik Kristianslund⁴, Sella Provan⁴, Tore Kvien⁵ and Daniel Aletaha⁶, ¹Medical University of Vienna, Wien, Austria, ²Medical University of Vienna, Vienna, Austria, ³Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, ⁴Diakonhjemmet Hospital, Oslo, Norway, ⁵Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, ⁶Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria, Wien, Austria
Background/Purpose: Measures of improvement and state of disease activity are well-established in rheumatoid arthritis (RA), whereas distinct classifiers for worsening (“flare”) are lacking to date.…
Abstract Number: 2406 • ACR Convergence 2023
Risk of Large Vessel Complications in Patients with Giant Cell Arteritis, a Population-based Study
Mohanad Elfishawi¹, Mahmut Kaymakci¹, Sara Achenbach², Cynthia Crowson¹, Tanaz Kermani³, Cornelia M. Weyand⁴, Matthew Koster¹ and Kenneth Warrington¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, MN, Rochester, MN, ³University of California Los Angeles, Los Angeles, CA, ⁴Mayo Clinic School of Medicine and Stanford University, Rochester, MN
Background/Purpose: Large vessel (LV) complications are known to occur in patients with giant cell arteritis (GCA). The magnitude of risk compared to the general population…
Abstract Number: 2278 • ACR Convergence 2023
Pregnancy in Connective Tissue Diseases: A 30 Year Follow-up Study of 465 Pregnancies from a Spanish Monocentric Registry
Cristiana Sieiro Santos¹, Paula Pérez García², Jose Ordas Martínez², Clara Moriano², Carolina Álvarez Castro² and Elvira Díez Álvarez², ¹Complejo Asistencial Universitario de León, León, Spain, ²CAULE, León, Spain
Background/Purpose: Pregnancy in patients with connective tissue diseases are known to be at high risk for the occurrence of adverse pregnancy outcomes. We aim toevaluate…
Abstract Number: 2474 • ACR Convergence 2023
Uveitis as Predictor of Disease Flare After the First Course of Anti-TNF Withdrawal in Oligo and Polyarticular Juvenile Idiopathic Arthritis: A Multicentric Italian Experience
Ilaria Maccora¹, Valerio Accardo², Marco Cattalini³, ilaria Pagnini⁴, Andrea Taddio⁵, Edoardo Marrani⁶, francesco La Torre⁷, Matteo Trevisan⁸, Maria Vincenza Mastrolia⁹ and Gabriele Simonini¹⁰, ¹PhD student, in the Area of Drugs and Innovative Treatments, NeuroFARBA Department, University of Florence. Meyer Children's Hospital, Firenze, Italy, ²University of Florence, Florence, Italy, ³Spedali Civili di Brescia, Brescia, Italy, ⁴Meyer Children's Hospital IRCCS, Florence, Italy, ⁵Rheumatology Unit, IRCCS Burlo Garofalo, Trieste, Italy, ⁶University of Florence, Firenze, Italy, ⁷Giovanni XXIII Pediatric Hospital, University of Bari, Bari, Italy, ⁸IRCCS Burlo Garofalo, Trieste, Italy, ⁹NEUROFARBA Department, University of Florence, Florence, Italy, ¹⁰Rheumatology Unit, ERN ReConnet Center, Meyer Children's Hospital IRCCS, Florence Italy. NeuroFARBA Department, University of Florence, Florence, Italy
Background/Purpose: TNF inhibitors (TNFi) have dramatically changed the prognosis of Juvenile Idiopathic Arthritis (JIA). However, once achieved disease remission, it is not clear how and…
Abstract Number: 2481 • ACR Convergence 2023
Pre-pregnancy Gene Expression Signatures Among Women with Rheumatoid Arthritis May Represent Predictive Biomarkers for Subsequent Improvement or Worsening During Pregnancy
Matthew Wright¹, Mette Smed², Lee Nelson³, Jørn Olsen⁴, Merete Hetland⁵, Nicholas Jewell⁶, Vibeke Zoffmann² and Damini Jawaheer¹, ¹Northwestern University, Chicago, IL, ²Juliane Marie Centre, Rigshospitalet, Copenhagen, Denmark, ³Fred Hutchinson Cancer Center, Seattle, WA, ⁴Aarhus University Hospital, Aarhus, Denmark, ⁵Copenhagen Center for Arthritis Research, Rigshospitalet, Copenhagen, Denmark, ⁶London School of Hygiene and Tropical Medicine, London, United Kingdom
Background/Purpose: Rheumatoid arthritis (RA) can improve naturally during pregnancy in a substantial proportion of women (50-75%), while it may worsen or remain unchanged in others.…
Abstract Number: 2502 • ACR Convergence 2023
Self-Reported Sleep Disorders Among Individuals with Systemic Lupus Erythematosus
Patti Katz¹, Maria Dall'Era², Jinoos Yazdany³ and Kaleb Michaud⁴, ¹University of California San Francisco, San Rafael, CA, ²University of California San Francisco, San Francisco, CA, ³University of California, General Department of Medicine, Division of Rheumatology, San Francisco, CA, ⁴University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Research in the general population has linked sleep disorders to poor outcomes such as lower pain thresholds, fatigue, cognitive impairment, depression, and cardiovascular disease…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].